Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
retapamulin · 1 trial · 1 indication
Area under the plasma concentration curve (AUC) is used to calculate drug clearance and bioavailability using plasma concentration and time curve.
Area under the plasma concentration curve (AUC) is used to calculate drug clearance and bioavailability using plasma concentration and time curve.
Cmax is the peak serum concentration. Low value was not calculable, and High value was 2.74 ng/mL.
Cmax is the peak serum concentration. Low value was not calculable, and high value was 2.74 ng/mL
Subjects who tested positive as persistent carriers of S. Aureus who on day 12 are negative and have been eradicated of S. Aureus.
| Arm | Type | Description |
|---|---|---|
| Treatment B | EXPERIMENTAL | 200mg BID retapamulin 5 days |
| Treatment C | PLACEBO_COMPARATOR | 200mg BID placebo 5 days |
| Treatment A | EXPERIMENTAL | 200mg BID retapamulin 3 days and placebo BID 2 days for a total of 5 days |
| Name | Type | Description |
|---|---|---|
| retapamulin | DRUG | 200mg BID retapamulin 3 days |
| Placebo | DRUG | 200mg BID placebo 5 days |
Inclusion Criteria: * Male and female subjects between the ages of 18 and 65, inclusive. A female is eligible to enter and participate in this study if she is non-pregnant, nonlactating and if she is of: * non-childbearing potential (i.e., physiologically incapable of becoming pregnant), includi...
Retapamulin, 1% is a small molecule antibiotic used for bacterial skin infections and other bacterial infections. It is being developed by GSK plc (ticker: GSK) and is currently in Phase 3 clinical development for these indications.
Retapamulin, 1% is an antibiotic that works by inhibiting bacterial protein synthesis. It is being studied for the treatment of bacterial skin infections and other bacterial infections, including those caused by Staphylococcus aureus.
Retapamulin, 1% is being developed by GSK plc, a global pharmaceutical company listed on the stock exchange under the ticker GSK. The drug is currently in Phase 3 clinical trials for bacterial skin infections.
Retapamulin, 1% is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials are ongoing to evaluate its safety and efficacy for bacterial skin infections.
Retapamulin, 1% has been studied in clinical trials including NCT00539994, a Phase 2 study in healthy adults nasally colonized with Staphylococcus aureus, and NCT00684177, a Phase 3 study in patients with secondarily-infected traumatic lesions. Both trials have been completed.
Retapamulin, 1% is also known by the brand name Altabax. It is an antibiotic ointment used to treat bacterial skin infections. The drug is being developed by GSK plc and is currently in Phase 3 clinical trials.